{"id":18395,"date":"2023-05-25T11:48:00","date_gmt":"2023-05-25T03:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18395"},"modified":"2024-12-17T11:51:13","modified_gmt":"2024-12-17T03:51:13","slug":"vcanbio-initiates-phase-ii-clinical-study-for-dental-pulp-stem-cell-injection-in-periodontitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18395","title":{"rendered":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis"},"content":{"rendered":"\n

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645<\/a>) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement in the field of regenerative medicine.<\/p>\n\n\n\n

Understanding Periodontitis and Its Impact<\/strong>
Periodontitis, also known as gum disease, is a serious gum infection that damages the soft tissue around teeth. If left untreated, it can destroy the bone that supports teeth, leading to tooth loss. In China, approximately 62.3% of adults aged 35 and above suffer from varying degrees of periodontitis, including 97.9 million patients with moderate to severe conditions. Chronic periodontitis has a wide range of clinical treatment needs, and existing treatment methods primarily rely on traditional treatments such as deep cleaning or, in severe cases, surgery.<\/p>\n\n\n\n

The Potential of Stem Cell Therapy in Periodontitis Treatment<\/strong>
Vcanbio’s human dental pulp mesenchymal stem cell injection offers a novel approach to treating chronic periodontitis. By leveraging the regenerative capabilities of stem cells, this therapy has the potential to revolutionize the treatment landscape for periodontitis, providing an alternative to traditional methods and offering hope for patients suffering from this common dental condition.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[77,62,1039,243],"class_list":["post-18395","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-sha-600645","tag-vcanbio-cell-gene-engineering"],"yoast_head":"\nVcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement in the field of regenerative medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18395\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18395\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-25T03:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-17T03:51:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis\",\"datePublished\":\"2023-05-25T03:48:00+00:00\",\"dateModified\":\"2024-12-17T03:51:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395\"},\"wordCount\":224,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"SHA: 600645\",\"Vcanbio Cell & Gene Engineering\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18395#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18395\",\"name\":\"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-05-25T03:48:00+00:00\",\"dateModified\":\"2024-12-17T03:51:13+00:00\",\"description\":\"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement in the field of regenerative medicine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18395\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18395#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis - Insight, China's Pharmaceutical Industry","description":"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement in the field of regenerative medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18395","og_locale":"en_US","og_type":"article","og_title":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18395","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-05-25T03:48:00+00:00","article_modified_time":"2024-12-17T03:51:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18395#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18395"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis","datePublished":"2023-05-25T03:48:00+00:00","dateModified":"2024-12-17T03:51:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18395"},"wordCount":224,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cell-therapy","Clinical trial approval \/ initiation","SHA: 600645","Vcanbio Cell & Gene Engineering"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18395#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18395","url":"https:\/\/flcube.com\/?p=18395","name":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-05-25T03:48:00+00:00","dateModified":"2024-12-17T03:51:13+00:00","description":"China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement in the field of regenerative medicine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18395#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18395"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18395#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Vcanbio Initiates Phase II Clinical Study for Dental Pulp Stem Cell Injection in Periodontitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18395"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18395\/revisions"}],"predecessor-version":[{"id":18396,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18395\/revisions\/18396"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}